Serendipity Biopharma (NASDAQ: LQDA) lists April 2026 10b5-1 and insider sales

Rhea-AI Filing Summary

Serendipity Biopharma (LQDA) reported multiple Form 144 sale notifications showing controlled sales of common stock by related parties. The excerpt lists scheduled 10b5-1 sales and an individual sale, including 25,000 shares on 04/16/2026 for $1,007,800 and 32,744 shares on 04/13/2026 for $1,256,387.28. The filings identify 10b5-1 plan activity and a sale attributed to Roger Jeffs; timing and plan mechanics are shown by sale dates in April 2026.

Insights

Securities Lawyer

Form 144 listings primarily document planned sales under Rule 10b5-1 and an individual disposition.

These entries list multiple sale dates and proceeds, indicating dispositions were reported pursuant to Section 144 procedures. The presence of 10b5-1 sales suggests pre-arranged trading plans; the filings themselves record the amounts and dates but do not change legal status of the securities.

Cash‑flow treatment is shown as sale proceeds per line items. Subsequent filings would be needed to confirm settlement details or any additional transfer mechanics.

Equity Markets Analyst

Repeated small-to-mid sized sales in April 2026 reflect routine liquidity events rather than a single large block disposition.

The sequence of 10b5-1 transactions (e.g., 25,000 shares on 04/16/2026) and one larger 32,744-share sale on 04/13/2026 implies staged selling across trading days. Volume per date is explicit in the excerpt.

Market impact depends on the company float and trading volume not shown here; future trade reports or amendments would clarify any ongoing selling cadence.

Key Figures

Sale on 04/16/2026: 25,000 shares Sale on 04/15/2026: 25,000 shares Sale on 04/14/2026: 3,300 shares +3 more

6 metrics

Sale on 04/16/2026 25,000 shares 10b5-1 sale for $1,007,800

Sale on 04/15/2026 25,000 shares 10b5-1 sale for $1,003,522.50

Sale on 04/14/2026 3,300 shares 10b5-1 sale for $132,000.00

Sale on 04/13/2026 32,744 shares Sale attributed to Roger Jeffs for $1,256,387.28

Sale on 04/10/2026 21,433 shares 10b5-1 sale for $859,876.96

Sale on 04/09/2026 25,000 shares 10b5-1 sale for $1,002,887.50

Key Terms

10b5-1, Form 144, Issuer

3 terms

10b5-1 regulatory

"10b5-1 Sales for SERENDIPITY BIOPHARMA LLC 419 Davis Drive"

A 10b5-1 plan is a pre-set schedule that lets company insiders buy or sell shares according to written instructions made when they do not possess material, nonpublic information. Think of it as a timed automatic payment for stock trades: it helps insiders avoid accusations of trading on secret information and gives outside investors a clearer signal about whether sales are routine or potentially informative about the company’s prospects.

Form 144 regulatory

"144: Securities Sold During The Past 3 Months"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Issuer other

"Merger or Acquisition | Issuer | 68839 | 11/18/2020"

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	68839	2849934.60	88114429	04/17/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/18/2020	Merger or Acquisition	Issuer			68839	11/18/2020	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for SERENDIPITY BIOPHARMA LLC 419 Davis Drive, Suite 100, Morrisville NC 27560	Common	04/16/2026	25000	1007800.00
10b5-1 Sales for SERENDIPITY BIOPHARMA LLC 419 Davis Drive, Suite 100, Morrisville NC 27560	Common	04/15/2026	25000	1003522.50
10b5-1 Sales for SERENDIPITY BIOPHARMA LLC 419 Davis Drive, Suite 100, Morrisville NC 27560	Common	04/14/2026	3300	132000.00
ROGER JEFFS 419 Davis Drive, Suite 100, Morrisville NC 27560	Common	04/13/2026	32744	1256387.28
10b5-1 Sales for SERENDIPITY BIOPHARMA LLC 419 Davis Drive, Suite 100, Morrisville NC 27560	Common	04/10/2026	21433	859876.96
10b5-1 Sales for SERENDIPITY BIOPHARMA LLC 419 Davis Drive, Suite 100, Morrisville NC 27560	Common	04/09/2026	25000	1002887.50

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for LQDA show about insider sales?

The Form 144 lists multiple sales of common stock by related parties. It documents scheduled 10b5-1 plan sales and a sale by Roger Jeffs with dates and proceeds in April 2026.

How many shares were sold under 10b5-1 on 04/16/2026 for LQDA?

The filing shows a 10b5-1 sale of 25,000 shares on 04/16/2026 for $1,007,800. The line item records share count and gross proceeds for that date.

Who is identified as selling shares in the LQDA excerpt?

The excerpt identifies SERENDIPITY BIOPHARMA LLC as conducting multiple 10b5-1 sales and lists Roger Jeffs for a sale on 04/13/2026. Each entry includes date, share count, and proceeds.

Are the sales in the Form 144 part of a 10b5-1 plan for LQDA?

Yes, several entries are labelled as 10b5-1 Sales, indicating pre-arranged trading plans. The filing lists specific sale dates and amounts consistent with scheduled plan executions.

Do the Form 144 lines provide settlement or buyer details for LQDA trades?

No. The excerpt lists sale dates, share counts, and gross proceeds but does not disclose counterparties, settlement mechanics, or post-transaction holdings in the provided lines.